Patent · US Expired

Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including plasmodium SPP

US8206725B2 · kind B2 · utility

0Cited by
3References
27Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJun 30, 2004
Grant dateJun 26, 2012
Priority date
Expiry dateJun 30, 2024

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to an immunogenic agent comprising a low dose of an antigenic component from one or more pathogens and an agent capable of increasing an amount of IL-12 in animal, and use thereof for reducing infection or improving recovery from an infection from the pathogen. The immunogenic agent preferably comprises CpG nucleic acid, IL-12 protein and/or IL-12 nucleic acid. The pathogen is preferably an intracellular pathogen comprising one or more species and strains, such as Plasmodium spp. The invention also relates to a pharmaceutical composition comprising the immunogenic agent. The pharmaceutical composition is preferably an immunotherapeutic composition. The immunotherapeutic composition, is preferably a vaccine capable of providing protection against or treating Plasmodium spp infection, the causative agent of malaria in humans.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.